Esperion Therapeutics ESPR Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's accounts receivable?
- Esperion Therapeutics (ESPR) reported accounts receivable of $132.35M in Q1 2026.
- How has Esperion Therapeutics's accounts receivable changed year-over-year?
- Esperion Therapeutics's accounts receivable increased by 62.8% year-over-year, from $81.29M to $132.35M.
- What is the long-term trend for Esperion Therapeutics's accounts receivable?
- Over 4 years (2021 to 2025), Esperion Therapeutics's accounts receivable has grown at a 52.1% compound annual growth rate (CAGR), from $83.75M to $448.21M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.